-
Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
On April 10th, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China announced that the clinical trial application for the Class 1 new oral ...- Ty奇葩罗牛山831
- 2024-4-11 19:03
- 支持
- 反对
- 回复
- 收藏